TriMix MEL

Drug Profile

TriMix MEL

Alternative Names: ECI-001; ECI-003; ECI-006; ECI-007; TriMix immunotherapies; TriMix immunotherapies - eTheRNA immunotherapies

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer eTheRNA Immunotherapies; Vrije Universiteit Brussel
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Malignant melanoma
  • Phase I Hepatocellular carcinoma; HIV infections
  • Preclinical Hepatitis B; Human papillomavirus infections

Most Recent Events

  • 14 May 2018 eTheRNA plans additional clinical trials in Malignant melanoma and Breast cancer in 2018 or 2019
  • 20 Mar 2018 eTheRNA immunotherapies plans to initiate enrolment for the high dose cohort in phase Ib/II trial for Melanoma, in second quarter of 2018
  • 19 Mar 2018 eTheRNA immunotherapies completes enrolment in its phase Ib trial for Melanoma in Belgium and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top